April 25, 2012

Deutsche Bank exits Actavis loan

Deutsche Bank (XETRA: DBKGn.DE / NYSE: DB) announced today that it will exit its exposure to Actavis, the generic pharmaceuticals company, upon completion of Watson Pharmaceuticals' acquisition of Actavis.

This triggered an impairment charge of EUR 257 million in the first quarter. The transaction is expected to close in the fourth quarter of 2012, at which time there will be Core Tier 1 capital accretion of approximately EUR 290 million.

Overall, it will have a net positive impact on the Group's Core Tier 1 capital ratio of approximately 6 basis points in 2012. This further demonstrates the Group's commitment to reducing non-core legacy positions and associated risk in a capital efficient manner.

For further information, please call:

Deutsche Bank AG
Press & Media Relations

Libby Young
Phone: +44 (0) 20 754 56941
E-mail: libby.young@db.com

Armin Niedermeier
Phone: +49 (0) 69 910 33402
E-mail: armin.niedermeier@db.com


Footer Navigation:
Last Update: April 26, 2012
Copyright © 2017 Deutsche Bank AG, Frankfurt am Main
This website uses cookies in order to improve user experience. If you close this box or continue browsing, we will assume that you are happy with this. For more information about the cookies we use or to find out how you can disable cookies, see our Cookies Notice.